For the quarter ended September 2025, Ultragenyx (RARE) reported revenue of $159.93 million, up 14.7% over the same period last year. EPS came in at -$1.81, compared to -$1.40 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $167.55 million, representing a surprise of -4.55%. The company delivered an EPS surprise of -47.15%, with the consensus EPS estimate being -$1.23.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Ultragenyx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product sales- Dojolvi: $24.28 million versus the eight-analyst average estimate of $25.96 million. The reported number represents a year-over-year change of +13.6%.
- Revenues- Product sales- Evkeeza: $16.72 million versus $13.24 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +56.9% change.
- Revenues- Product sales- Mepsevii: $7 million compared to the $8.82 million average estimate based on eight analysts. The reported number represents a change of -27.2% year over year.
- Revenues- Total Crysvita revenue: $111.94 million versus the six-analyst average estimate of $119.46 million.
- Revenues- Product sales: $94.99 million versus the five-analyst average estimate of $89.79 million. The reported number represents a year-over-year change of +23%.
- Revenues- Royalty revenue: $64.94 million versus $78.87 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +4.3% change.
View all Key Company Metrics for Ultragenyx here>>>
Shares of Ultragenyx have returned +10.9% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
